Cannabis honestly examined

Medicine and risk at the same time.
Both are true.

What cannabis can do as therapy. Where the addiction risk sits biologically. Why fatigue comes from your mitochondria, not from your character. And which paths exist to reduce pain, sleep better and become clear again, without cannabis.

My position

I am a doctor. I prescribe medical cannabis in my practice for clear indications, when the benefit outweighs the harm. And at the same time I see what high-potency consumption may do to young people.

Both are true. Cannabis is medicine for a small, clearly defined group. Cannabis is risk for a large, often invisible group. Anyone who tells only one of those two truths is lying by omission.

This article is the honest dual view. From the perspective of clinical psychoneuroimmunology. From functional medicine. From anthroposophic medicine. With studies. And with what you can do today to reduce pain, sleep better and become calmer, without cannabis.

Why this article is needed right now

Before we go into the biology, a picture has to land that many patients do not yet know in this form. Since 1 April 2024, cannabis has been removed from the German narcotics law and can be prescribed on a normal eRecipe. That was regulatory progress. What has come of it in practice needs explaining.

+3300%
Increase in cannabis prescriptions in Germany between March 2024 and December 2025
~900,000
Patients by mid 2025, up from around 250,000 in April 2024
+170%
Increase in cannabis imports in late 2024, far faster than the prescription numbers

A large share of this boom runs through telemedicine platforms that issue cannabis prescriptions after an online questionnaire, often without a personal consultation, without a physical examination, without long-term follow-up. The German Federal Ministry of Health has reacted and plans to require at least one in-person initial contact before any cannabis prescription, plus a ban on mail-order sales of cannabis flower.

Why does this matter for you? Because a prescription alone is not therapy. A prescription without a doctor-patient relationship, without a diagnosis, without follow-up may do exactly what cannabis most often does: dampen a symptom while the cause keeps growing. The fact that it is fast and easy today to obtain a cannabis prescription does not mean it is the right therapy for you. It only means that the market has a very low entry barrier.

Reframe

Easy access to a substance is no indicator of its appropriateness. The question is not whether you can get cannabis. The question is whether cannabis serves your specific problem, or whether it is a tool that displaces other tools that would be more sustainable.

What cannabis really does in your body

Before we talk about benefit and risk, let us briefly look at the biology. Your body has its own cannabis system. It is called the endocannabinoid system, ECS for short. It regulates mood, pain, appetite, sleep, immune function and stress response. You have it long before you have ever thought about cannabis.

Two receptor families carry the system. CB1 sits mainly in the brain and nervous system. CB2 sits mainly on immune cells. Your body produces its own cannabinoids, especially anandamide, often called the "bliss molecule" because its name comes from the Sanskrit word for bliss.

Cannabis brings two main molecules into play. THC binds strongly to CB1, is psychoactive, has analgesic and appetite-stimulating effects. CBD acts indirectly on the ECS, dampens THC's effect, is not psychoactive, and has anxiolytic, anti-inflammatory and anticonvulsant effects of its own.

Reframe

Cannabis is not a foreign substance. It is a body-internal system that you trigger from outside with an extremely strong dose. The question is not whether it works, but what that dose does to the system over time.

The mitochondria story: why fatigue comes from your cells, not from your head

Here comes the point that most patients hear for the first time. It is neurobiologically decisive.

For a long time, science assumed CB1 receptors sit only on the cell membrane of nerve cells. In 2012, Bénard's team found something else. CB1 receptors also sit directly on the mitochondria, the power plants of your cells. They are called mtCB1.

Mechanism Bénard 2012, Nature Neuroscience

Bénard and colleagues were the first to demonstrate functional CB1 receptors on the membranes of neuronal mitochondria. Activation of mtCB1 lowers cAMP, dampens activity of complex I in the respiratory chain and reduces mitochondrial respiration. Translation: cannabis directly reaches into your cellular energy production.

Bénard G et al. Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci. 2012;15(4):558 to 564. DOI: 10.1038/nn.3053

Mechanism Hebert-Chatelain 2016, Nature

Four years later Hebert-Chatelain showed: cannabis-induced memory impairment disappears if you genetically remove only the mitochondrial CB1 receptors. That proves that the cognitive dampening of cannabis works not only through synaptic effects, but through the energy supply of the brain cells.

Hebert-Chatelain E et al. A cannabinoid link between mitochondria and memory. Nature. 2016;539(7630):555 to 559. DOI: 10.1038/nature20127

In vitro THC and ATP

In brain tissue studies, THC throttles maximal mitochondrial oxidative capacity by 71 percent and respiratory activity by 65 percent. ATP production falls dose-dependently. Effects last for hours.

Wolff V et al. Tetrahydrocannabinol Induces Brain Mitochondrial Respiratory Chain Dysfunction. Biomed Res Int. 2015;323706. DOI: 10.1155/2015/323706

What does that mean in practice? The well-known cannabis aftermath of heaviness, sluggishness, low drive the next day is not psychological. It is not "I have just become lazier". It is less ATP in your brain cells. Your cells literally have less power. Consciousness slows down because the machinery that carries it has less energy.

On top of that comes a second layer. In chronic users, striatal dopamine synthesis is reduced, and that finding correlates directly with apathy scores. You are not losing drive because you are weak. You are losing it because your reward system is producing objectively less dopamine.

PET Bloomfield 2014, Biological Psychiatry

Using PET imaging, Bloomfield and colleagues showed: cannabis-dependent persons have reduced striatal dopamine synthesis capacity, and the lower the synthesis, the higher the measured apathy score. That is the biological floor for what is colloquially called "amotivational syndrome".

Bloomfield MAP et al. Dopaminergic Function in Cannabis Users. Biol Psychiatry. 2014;75(6):470 to 478. DOI: 10.1016/j.biopsych.2013.05.027

Reframe

If you feel more tired, slower, less motivated after extended cannabis use, you have not developed a character flaw. You have a measurable cellular energy crisis. Character returns when the mitochondria are allowed to work at full capacity again.

What cannabis as medicine can credibly do

Cannabis has clean medical indications. I prescribe it. The important caveat: not for everything, not in every form, not for every person.

Meta Whiting 2015, JAMA

The most important review of all medical cannabis indications. Best evidence was found for chronic pain, multiple sclerosis spasticity, and chemotherapy-induced nausea. Limited or unclear evidence for sleep, Tourette, HIV cachexia, glaucoma, anxiety, depression. The effects are real, but more modest than public discussion often suggests.

Whiting PF et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456 to 2473. DOI: 10.1001/jama.2015.6358

RCT Sativex for MS spasticity

Nabiximols (Sativex), an oromucosal spray of THC and CBD, is approved in Germany for patients with treatment-resistant spasticity in multiple sclerosis. Multiple Phase III RCTs show significant reduction of spasticity NRS and daily spasm count, especially as add-on therapy. Here the evidence is robust.

Wade DT et al. Sativex in refractory MS spasticity. Mult Scler. 2010;16(6):707 to 714. DOI: 10.1177/1352458510367462

RCT Devinsky 2017, NEJM

In children with Dravet syndrome, a severe drug-resistant epilepsy, pure CBD reduced convulsive seizure frequency by approximately 39 percent. A parallel 2018 trial showed similar effects in Lennox-Gastaut syndrome. CBD is approved as Epidiolex. A rare but undisputed indication.

Devinsky O et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med. 2017;376(21):2011 to 2020. DOI: 10.1056/NEJMoa1611618

Cochrane Mücke 2018, neuropathic pain

16 RCTs, 1750 patients with chronic neuropathic pain. Cannabis-based medicine performed better than placebo, with a moderate effect. The authors phrased it cautiously: the potential benefit may be outweighed by side effects. No miracle cure, but an option when other paths are exhausted.

Mücke M et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182. DOI: 10.1002/14651858.CD012182.pub2

Beyond that, there are smaller positive signals for CBD in social phobia (Bergamaschi 2011, Crippa 2011) and for cannabinoids in chemotherapy-induced nausea as a reserve option, when modern antiemetics fail. The evidence for sleep disorders and general anxiety is much thinner than marketing often suggests.

Where the evidence has gaps you should know about

Cannabis is often presented as a universal solution. For sleep, for stress, for anxiety, for "inner restlessness". Honestly, this is a marketing phenomenon, not a research finding.

For sleep disorders, cannabis has acute sedative effects, but chronic users develop tolerance. On withdrawal, sleep often gets dramatically worse (withdrawal insomnia), which keeps the consumption going without the underlying cause being addressed. For anxiety, CBD acts anxiolytically in low doses, while THC often produces paradoxical anxiety, especially at higher doses or in predisposed individuals. For depression and PTSD, the evidence is mixed, with signals that chronic use may worsen outcomes.

Reframe

If cannabis acutely helps you sleep or calm down, that is real. But subjective relief is not proof of efficacy. And it is certainly not proof that cannabis is the best thing you can do for your sleep or your anxiety.

Addiction risk is biology, not weakness

Here it gets uncomfortable. Cannabis has a clearly documented addictive potential. To deny that is to whitewash.

22 to 27%
Lifetime risk among users of developing a Cannabis Use Disorder
6.3%
Lifetime prevalence of Cannabis Use Disorder in US adults
16.6%
Past-year prevalence of CUD among 18 to 25 year olds
NESARC-III Hasin 2016, Am J Psychiatry

36,309 US adults were systematically interviewed. Result: about a quarter of all people who have ever used cannabis meet DSM-5 criteria for a Cannabis Use Disorder at some point. Frequency, potency and early onset increase the risk.

Hasin DS et al. Prevalence and Correlates of DSM-5 Cannabis Use Disorder. Am J Psychiatry. 2016;173(6):588 to 599. DOI: 10.1176/appi.ajp.2015.15070907

On top comes the Cannabis Withdrawal Syndrome, officially recognized in DSM-5. About 12 percent of frequent users experience irritability, anxiety, sleep disturbance, depressed mood, appetite loss, sometimes sweating and tremor on cessation. The classic "I can quit anytime" is often relativised within the first week of quitting. Anyone who has experienced it physically knows: this is not willpower, this is pharmacology.

Two thresholds you must know: adolescence and high potency

There are two constellations where the evidence is so clear that minimisation no longer holds.

Cohort Meier 2012, PNAS Dunedin

1037 New Zealanders, prospectively followed from birth to age 38. IQ tested at age 13 (before any cannabis exposure) and at age 38. Adolescent-onset persistent users lost on average 8 IQ points. Adult-onset users showed no measurable IQ loss. The adolescent brain is in a critical maturation phase that is not made up later.

Meier MH et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109(40):E2657 to E2664. DOI: 10.1073/pnas.1206820109

Meta Marconi 2016, Schizophrenia Bulletin

Meta-analysis of 66,816 individuals. Heaviest cannabis users have an odds ratio of 3.90 for schizophrenia and psychosis spectrum diagnoses, compared to non-users. Clear dose-response relationship. Causality is not finally proven, but this is the strongest risk constellation in cannabis research.

Marconi A et al. Cannabis Use and Risk of Psychosis Meta-analysis. Schizophr Bull. 2016;42(5):1262 to 1269. DOI: 10.1093/schbul/sbw003

EU-GEI Di Forti 2019, Lancet Psychiatry

Multicentre study, 901 first-episode psychosis patients plus 1237 controls from eleven European sites. Daily cannabis users had a threefold elevated risk of first-episode psychosis. Daily users of high-potency cannabis (THC over 10 percent) had a 4.8 times elevated risk. In London and Amsterdam, around 30 percent of new psychosis cases were attributable to high-potency consumption.

Di Forti M et al. Cannabis and Incidence of Psychotic Disorder EU-GEI. Lancet Psychiatry. 2019;6(5):427 to 436. DOI: 10.1016/S2215-0366(19)30048-3

Reframe

If you have a family history of psychosis, if you are younger than 25, or if you use high-potency cannabis daily, you are not in a grey zone. You are in the constellation with the highest measurable burden. Caution here is not paternalism, it is mathematics.

The anthroposophic view: cannabis and the awake "I"

From the perspective of anthroposophic medicine, the human being is threefold. There is the nerve-sense system (consciousness, clarity, alertness, differentiation). There is the rhythmic system (breathing, heart, feeling, the centre). And there is the metabolic-limb system (will, digestion, warmth, movement). Health is balance between these three poles.

Cannabis shifts this balance characteristically. It dampens the awake nerve-sense system and amplifies the dreaming, dissolving pole. In Steiner's language: it pushes the human being towards the luciferic pole, away from sharp differentiation. That is exactly what makes the subjective appeal: the "becoming softer", the "letting go", the "sliding into images".

For controlled, occasional use, this shift is not a problem. With chronic use, something else happens. The awake "I", the middle force that balances between dream and hardening, becomes quieter. Differentiation gets harder. Decisions get softer. Perception becomes less precise. The clinical observation maps strikingly onto the mitochondrial finding above: less energy for consciousness means a quieter awake "I".

From the anthroposophic angle

Anthroposophic medicine does not say "cannabis is evil". It says: honour the clarity of your "I". Ask yourself: when do I need this substance because life right now demands something I cannot otherwise carry, and when do I use it to avoid the clarity that life is currently asking of me?

If the answer is consistently the second, then cannabis works against what the human being is meant to do: stay awake, present, and able to discern.

PNI and functional medicine: root work instead of symptom dampening

Clinical psychoneuroimmunology does not look at the symptom but at four lenses: nervous system, immune system, metabolism, hormones. Cannabis dampens symptoms across all four lenses, without addressing the root cause.

If someone uses cannabis because they cannot sleep, the real question is not "does cannabis work for sleep". The real question is: why is your system not sleeping? Disrupted cortisol rhythm, blue light late at night, magnesium deficiency, unresolved conflict, caffeine-driven day, no morning daylight, mitochondrial weakness, inflammation, late sugar? That is PNI work. Cannabis helps short term. The causes do not change.

If someone uses cannabis for chronic pain, the question is: which of the four PNI lenses drives this pain? Nervous system on permanent alarm? Silent inflammation? Tissue mitochondrial weakness? Hormonal shifts? Here too, cannabis dampens. Roots remain untouched.

From a functional medicine perspective: any symptom dampening that is not combined with root work costs more long term than it saves short term.

How I work with cannabis in my practice

I do prescribe cannabis. But rarely as a first lever. And never without a clear diagnosis, without a personal consultation, without longer-term follow-up. There are three patient constellations where I actively consider cannabis as a therapy tool.

When cannabis can be a meaningful option in my view

1. Severe refractory spasticity in multiple sclerosis

Here the evidence for Sativex is robust. When classic antispastics are not enough or not tolerated, a cannabis spray may bring real functional improvement, without the typical sedating weakness of other antispastic drugs.

2. Treatment-resistant chronic neuropathic pain

When classic pain therapy, multimodal programmes, PNI work, exercise and targeted psychotherapy are not enough, cannabis as add-on is debatable. Mücke 2018 shows a moderate effect that is clinically relevant in some patients. I then talk about quality of life, not about cure.

3. Oncology support with nausea, appetite loss, sleep

In active cancer therapy, where nausea, lack of appetite and sleep disruption converge, dronabinol or nabilone is an established reserve option. Here the benefit is often clear and the addiction risk over a limited duration manageable.

What I have to say just as clearly: in the vast majority of cases where patients come to me asking for cannabis, the indication is not unambiguous. It is about sleep problems, stress, anxiety, diffuse pain, "I do not know how to come down anymore". For these themes, cannabis is in my view almost never the first choice. Not because it does nothing, but because other paths are demonstrably more sustainable and carry no addiction risk.

Reframe

A good doctor does not prescribe cannabis because the patient wishes it. A good doctor prescribes cannabis when the indication is clear and all other, less risky paths have been exhausted or are not possible. If the path to your cannabis prescription felt too easy, it may have been.

Other paths by indication

If you feel cannabis is the only thing that helps you, let us go through the evidence indication by indication. For the most common reasons people seek cannabis today, there are paths with better long-term evidence and no addiction risk.

Pain

Meta Exercise and pain

Structured exercise reduces chronic pain with effect sizes comparable to non-steroidal anti-inflammatory drugs, without their side effects. More importantly: at moderate intensity the body releases its own anandamide. That is your endogenous cannabinoid. You produce it yourself when you move.

Geneen LJ et al. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;4(4):CD011279. DOI: 10.1002/14651858.CD011279.pub3

Meta Omega-3 in chronic pain

41 RCTs, 3759 patients. Omega-3 fatty acids (EPA and DHA) reduce chronic pain with a moderate, clinically relevant effect. Mechanism: inhibition of pro-inflammatory prostaglandins, generation of pro-resolving mediators like resolvins, dampening of microglial activation.

Recent meta-analysis, Frontiers in Medicine 2025. DOI: 10.3389/fmed.2025.1654661

RCT LDN in fibromyalgia

Low-dose naltrexone (3 to 4.5 mg) reduced pain scores significantly in four randomised trials in fibromyalgia patients, with a good safety profile. Mechanism via transient opioid receptor blockade leading to elevated endorphin and enkephalin tone.

Soin A et al. Efficacy and safety of low-dose naltrexone for fibromyalgia: meta-analysis. 2024. DOI: 10.1093/pm/pnae101

Sleep

Meta CBT-I as first-line therapy

Cognitive behavioural therapy for insomnia is the first-line therapy for chronic insomnia in nearly all guidelines. It reduces sleep onset by an average of 19 minutes and wake time after sleep onset by 26 minutes. Unlike sleeping pills and unlike cannabis, CBT-I effects remain stable or even improve over 12 months.

Trauer JM et al. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(3):191 to 204. DOI: 10.7326/M14-2841

On top come the basics that many patients underestimate: dark, cool bedroom, no screens in the last hour before sleep, regular sleep times, magnesium in the evening (may support falling asleep), no caffeine after 2 pm, daylight in the first hour of the day for the cortisol axis. PNI-aligned additions: check the cortisol day profile, avoid evening blood sugar swings, surface unresolved themes instead of deckling them with a substance.

Stress and chronic overload

Stress is the most common self-justification that brings people to a joint in the evening. The evidence here is straightforward: there are three methods that, in direct comparison, work equally well, without addiction risk, without mitochondrial dampening, without sleep deterioration over time.

RCT Stress reduction directly compared

A randomised trial directly compared physical activity, mindfulness meditation, and HRV biofeedback. All three methods reduced stress and stress-related symptoms significantly, with no significant difference between them. That means: each of these three is a real, empirically supported alternative to an evening joint, with the bonus of HRV improvement.

van der Zwan JE et al. Physical Activity, Mindfulness Meditation, or HRV Biofeedback for Stress Reduction RCT. Appl Psychophysiol Biofeedback. 2015;40(4):257 to 268. DOI: 10.1007/s10484-015-9293-x

Meta HRV biofeedback in stress and anxiety

Meta-analysis of 14 RCTs with 794 participants. HRV biofeedback reduces self-reported stress and anxiety with a moderate effect size, comparable to classic relaxation methods. It directly trains the autonomic nervous system and is a central tool in my practice as an objectifiable measure.

Goessl VC et al. HRV biofeedback on stress and anxiety meta-analysis. Psychol Med. 2017;47(15):2578 to 2586. DOI: 10.1017/S0033291717001003

On top come the slower, deeper levers: anthroposophic compresses (lavender abdominal compress in the evening), warmth applications, contact with nature (a walk in the forest demonstrably reduces cortisol), relational clarity, honest communication. Whoever uses cannabis against stress dampens the symptom. Whoever works on these points relaxes the system.

Anxiety and inner restlessness

The most effective non-pharmacological levers: coherent breathing (four seconds in, six seconds out, five minutes daily) regulates the vagus nerve and measurably raises HRV. Mindfulness and MBSR reduce anxiety and pain with small to moderate effects across more than 30 RCTs. Exercise works as antidepressant and anxiolytic via endocannabinoids and BDNF. Targeted psychotherapy at the roots (trauma, conflicts, relationships) works more sustainably than any substance.

For generalised anxiety, the PNI lenses are worth checking: low magnesium may increase neuronal excitability, low vitamin D is associated with higher anxiety prevalence, thyroid and iron co-determine the tone. If one of these is off, even the most relaxing joint will not help sustainably.

Trauma and post-traumatic stress

This is where cannabis is particularly often used on personal initiative, with partly understandable subjective effects. The evidence shows a clear gap between subjective experience and durable healing.

Review Cannabis in PTSD

A systematic review of cannabis therapy in PTSD concluded: the available evidence is mostly of low quality, primarily single-arm observational studies. There are subjective symptom improvements, but no reliable data that cannabis processes the trauma itself. On the contrary: regular cannabis use is associated with higher dropout rates in trauma-focused therapy.

Rehman Y et al. Cannabis in the management of PTSD: a systematic review. AIMS Neuroscience. 2021;8(3):414 to 434. DOI: 10.3934/Neuroscience.2021022

What has real impact in trauma: EMDR (Eye Movement Desensitization and Reprocessing) with evidence from 24 RCTs, in several comparisons even faster than trauma-focused CBT. Trauma-focused CBT with prolonged exposure as first-line therapy. Somatic Experiencing as a body-oriented approach, especially for dissociative parts. EAET (Emotional Awareness and Expression Therapy) for somatised trauma sequelae with chronic pain. These methods work with the trauma. Cannabis works around it.

If you are young and use cannabis against life-feel themes

A particular constellation, because it is especially common today. Younger adults between 18 and 28 who use cannabis against "inner emptiness", "meaninglessness", "lack of depth", "too much overstimulation". Three points are important here: first, the adolescent and early-adult brain is in a critical maturation phase until the mid 20s. Second, high-potency material is in this constellation the largest risk factor for a first psychotic episode. Third, what often feels like "inner emptiness" is very often an unanswered hunger for meaning plus a measurable biological depletion (sleep, micronutrients, lack of movement, screen time, missing relational depth).

The most honest therapeutic answer here is a mixture of relational therapy, PNI diagnostics (thyroid, cortisol profile, vitamin D, iron, microbiome), physical activity, meaning work, and where appropriate anthroposophic support. Cannabis can soften this experiential gap acutely. It does not fill it.

Cannabis as a tool

Acutely effective, fast sedation, fast pain dampening, fast calming.

Tolerance, withdrawal, mitochondrial throttling, dopaminergic anhedonia. Root causes get covered, not treated.

Other paths

Exercise, breathing, CBT-I, omega-3, mindfulness, LDN for specific indications, root-level psychotherapy, targeted micronutrients.

Slower build-up, but stable, self-sustaining effects. No addiction risk. Energy is built up, not borrowed.

If you want to come off cannabis: what really helps

Anyone who uses regularly and wants to stop knows the pattern: a few days go well, then come sleep problems, irritability, vivid dreams, restlessness, the gnawing craving. Most self-quit attempts last less than a week. That is not weakness. That is withdrawal. It usually fades within two to four weeks, but the first ten days are hard.

You do not have to fight against the substance. You have to give the system what it expected from cannabis: calm, sleep, reward, meaning. By another route.

What studies show as effective

1. Reduce instead of cold-turkey

Studies on self-quitters show: those who already reduced in the two weeks before the quit date have significantly higher success rates and longer abstinence periods. The "100 to 0" jump often fails.

2. Cognitive Behavioural Therapy (CBT)

For cannabis dependence, CBT shows effect sizes of Cohen's d 0.53 to 0.9 in meta-analyses. That is moderate to large. It works on triggers, cravings, alternative strategies.

3. Contingency Management

Reward systems for negative urine tests are well documented in studies, especially in combination with CBT.

4. N-Acetylcysteine in adolescents

NAC 1200 mg twice daily doubled the rate of negative urine tests in a double-blind RCT among cannabis-dependent adolescents (OR 2.4). In adults, the effect was not reproducible in a large trial. In adolescents NAC may be considered, with medical supervision.

5. Endocannabinoid tone via exercise

Moderate-intensity exercise over 30 to 45 minutes measurably raises anandamide. That addresses exactly the system that cannabis artificially overrides. You give your body the signal it is seeking, and you refill the mitochondria at the same time.

6. Stabilise sleep first

Withdrawal insomnia is the most common relapse trigger. CBT-I principles, magnesium, cool dark room, no screens, daylight anchor in the morning. Sleep does not have to be perfect in the first weeks, it just has to be bearable.

7. Social and therapeutic support

Self-quit research shows: changes in environment, social support, and where appropriate professional accompaniment are by far the most common success strategies.

8. Anthroposophic support

In my practice I can offer anthroposophic support that specifically strengthens the clarity of the "I" and activates the metabolic-limb system that has been slowed by cannabis for a long time. Plant-based and anthroposophic remedies are not a replacement, but a meaningful accompanying layer.

Quality of life after abstinence

In a study of treatment-seekers with Cannabis Use Disorder, achieving abstinence brought a measurable increase in quality of life of 12 percent, equivalent to about one standard deviation in comparison cohorts. That is not "I feel a little better". That is objectively a different life.

Hser YI et al. Abstinence and Reduced Frequency of Use Are Associated With Improvements in Quality of Life Among Treatment-Seekers With Cannabis Use Disorder. Am J Addict. 2017. DOI: 10.1111/ajad.12597

Three honest levers for your self-check

First lever. Ask yourself the honest question: if I stop today, would I feel free energy, or a loss? If the answer is "loss", that is not proof that cannabis benefits you. It is proof that your system has adapted to the substance. That is exactly the definition of dependence.

Second lever. Breathe coherently for five minutes a day (four seconds in, six seconds out). This single exercise measurably raises your HRV in studies and lifts your endogenous endocannabinoid tone. You build up internally what you would otherwise take from outside.

Third lever. If you use cannabis, do it consciously, not reflexively. Never daily. Never as a permanent sleep aid. Never against stress that actually needs processing. Never in adolescence, never with a family history of psychosis, never daily and high-potency. If those lines are held, cannabis remains an occasional tool. If they blur, it becomes a load that your system measurably pays for.

True freedom

Clarity is not less pleasure. Clarity is the precondition for being able to enjoy fully. An awake person in a calm nervous system has more sensory depth than a dampened one. This freedom is reachable, it is biologically supported, and it is worth it.

If you do not only want to read but to work on your own personal relationship with cannabis, whether as therapy under medical supervision or as a path of liberation, you will find the option to book an appointment below this article. We measure, we listen, we build a plan that treats your biology, your story and your clarity as one unit.

Sources

  1. Bénard G et al. Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nat Neurosci. 2012;15(4):558 to 564. DOI: 10.1038/nn.3053
  2. Hebert-Chatelain E et al. A cannabinoid link between mitochondria and memory. Nature. 2016;539(7630):555 to 559. DOI: 10.1038/nature20127
  3. Wolff V et al. Tetrahydrocannabinol Induces Brain Mitochondrial Respiratory Chain Dysfunction. Biomed Res Int. 2015;323706. DOI: 10.1155/2015/323706
  4. Bloomfield MAP et al. Dopaminergic Function in Cannabis Users. Biol Psychiatry. 2014;75(6):470 to 478. DOI: 10.1016/j.biopsych.2013.05.027
  5. Whiting PF et al. Cannabinoids for Medical Use Meta-analysis. JAMA. 2015;313(24):2456 to 2473. DOI: 10.1001/jama.2015.6358
  6. Mücke M et al. Cannabis-based medicines for chronic neuropathic pain. Cochrane Database Syst Rev. 2018;3(3):CD012182. DOI: 10.1002/14651858.CD012182.pub2
  7. Wade DT et al. Sativex in refractory MS spasticity. Mult Scler. 2010;16(6):707 to 714. DOI: 10.1177/1352458510367462
  8. Devinsky O et al. Cannabidiol for Drug-Resistant Seizures in Dravet. NEJM. 2017;376(21):2011 to 2020. DOI: 10.1056/NEJMoa1611618
  9. Devinsky O et al. Cannabidiol on Drop Seizures in Lennox-Gastaut. NEJM. 2018;378(20):1888 to 1897. DOI: 10.1056/NEJMoa1714631
  10. Bergamaschi MM et al. Cannabidiol Reduces Anxiety in Social Phobia. Neuropsychopharmacology. 2011;36(6):1219 to 1226. DOI: 10.1038/npp.2011.6
  11. Hasin DS et al. DSM-5 Cannabis Use Disorder. Am J Psychiatry. 2016;173(6):588 to 599. DOI: 10.1176/appi.ajp.2015.15070907
  12. Bahji A et al. Cannabis Withdrawal Syndrome Prevalence Meta-Analysis. JAMA Netw Open. 2020;3(4):e202370. DOI: 10.1001/jamanetworkopen.2020.2370
  13. Marconi A et al. Cannabis Use and Risk of Psychosis Meta-analysis. Schizophr Bull. 2016;42(5):1262 to 1269. DOI: 10.1093/schbul/sbw003
  14. Di Forti M et al. Cannabis and Incidence of Psychotic Disorder EU-GEI. Lancet Psychiatry. 2019;6(5):427 to 436. DOI: 10.1016/S2215-0366(19)30048-3
  15. Meier MH et al. Persistent cannabis users show neuropsychological decline. PNAS. 2012;109(40):E2657 to E2664. DOI: 10.1073/pnas.1206820109
  16. Sorensen CJ et al. Cannabinoid Hyperemesis Syndrome. J Med Toxicol. 2017;13(1):71 to 87. DOI: 10.1007/s13181-016-0595-z
  17. McCartney D et al. Acute THC-induced driving impairment meta-analysis. Neurosci Biobehav Rev. 2021;126:175 to 193. DOI: 10.1016/j.neubiorev.2021.01.003
  18. Gray KM et al. NAC in Cannabis-Dependent Adolescents RCT. Am J Psychiatry. 2012;169(8):805 to 812. DOI: 10.1176/appi.ajp.2012.12010055
  19. Gates PJ et al. Psychosocial interventions for cannabis use disorder. Cochrane. 2016;5:CD005336. DOI: 10.1002/14651858.CD005336.pub4
  20. Trauer JM et al. CBT for Chronic Insomnia Meta-analysis. Ann Intern Med. 2015;163(3):191 to 204. DOI: 10.7326/M14-2841
  21. Geneen LJ et al. Physical activity and exercise for chronic pain. Cochrane. 2017;4:CD011279. DOI: 10.1002/14651858.CD011279.pub3
  22. Goldberg SB et al. Mindfulness Meditation for Chronic Pain Meta-analysis. Ann Behav Med. 2017;51(2):199 to 213. DOI: 10.1007/s12160-016-9844-2
  23. Bidonde J et al. Low-dose naltrexone for fibromyalgia meta-analysis. Pain Med. 2024. DOI: 10.1093/pm/pnae101
  24. Siebers M et al. Endocannabinoids and the Runner's High. Neuroscientist. 2023;29(3):352 to 369. DOI: 10.1177/10738584211069981
  25. Hser YI et al. Abstinence and Quality of Life in Cannabis Use Disorder. Am J Addict. 2017;26(7):685 to 691. DOI: 10.1111/ajad.12597
  26. Recent meta-analysis on omega-3 and chronic pain. Front Med. 2025. DOI: 10.3389/fmed.2025.1654661
  27. van der Zwan JE et al. Physical Activity, Mindfulness, HRV Biofeedback for Stress Reduction RCT. Appl Psychophysiol Biofeedback. 2015;40(4):257 to 268. DOI: 10.1007/s10484-015-9293-x
  28. Goessl VC et al. HRV Biofeedback on Stress and Anxiety Meta-analysis. Psychol Med. 2017;47(15):2578 to 2586. DOI: 10.1017/S0033291717001003
  29. Rehman Y et al. Cannabis in PTSD systematic review. AIMS Neuroscience. 2021;8(3):414 to 434. DOI: 10.3934/Neuroscience.2021022
  30. German Federal Ministry of Health. Medical Cannabis Act (MedCanG), in force since 1.4.2024. Planned amendment 2025/2026: mandatory in-person initial consultation before any cannabis prescription, ban on mail-order sales of cannabis flower.
  31. Market data Germany. Increase in medical cannabis prescriptions of around 3300 percent between March 2024 and December 2025; estimated patient numbers from around 250,000 (April 2024) to around 900,000 (mid 2025).
A note on the evidence: This article combines tier 1 evidence (meta-analyses, Cochrane reviews, large RCTs) with mechanistic evidence (mtCB1, mitochondria, dopamine PET) and clinical observations from practice plus the anthroposophic tradition. Cannabis as medicine may help a clearly defined patient group. The translation of individual successes or risks is always a probability, never a guarantee. Anyone who regularly uses cannabis or considers a prescription should discuss it with their physician personally.

Have questions or want to book an appointment?

We'd be happy to advise you personally at our practice.

Book appointment